logo

Atossa Genetics, Inc. (ATOS)



Trade ATOS now with
  Date
  Headline
10/16/2019 8:37:55 AM Atossa Genetics Receives IRB Approval For Phase 2 Breast Cancer Study Using Intraductal Technology
9/30/2019 8:38:15 AM Atossa Reports Preliminary Results From Phase 1 Study Of Proprietary Modified-release Tablet Form Of Oral Endoxifen
9/3/2019 8:17:55 AM Atossa Genetics Completes Enrollment And Dosing In Phase 1 Clinical Trial
7/11/2019 8:39:37 AM Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Begins Phase 1 Clinical Trial
6/27/2019 8:13:49 AM Atossa Genetics’ Preliminary Phase 2 Study Of Proprietary 20mg Daily Topical Z Endoxifen Achieves Primary Endpoint
3/14/2019 8:37:07 AM Atossa Genetics Announces FDA Approval Of Oral Endoxifen For “Expanded Access” As Post-Mastectomy Treatment
2/4/2019 8:37:17 AM Atossa Genetics Provides Breast Cancer Prevention Recommendations To USPSTF
1/9/2019 8:39:12 AM Atossa Genetics Reports Final Results From Phase 1 Dose-escalation Study Of Endoxifen In Male Subjects
12/3/2018 8:14:16 AM Atossa Genetics : FDA Oks Endoxifen For “Expanded Access” As Preoperative Systemic Endocrine Therapy For Breast Cancer
10/11/2018 8:06:53 AM Atossa Genetics Completes Enrollment In Phase 2 Study Of Topical Endoxifen In Women With Mammographic Breast Density
6/26/2018 8:07:06 AM Atossa Genetics Opens Its Phase 2 Study Of Topical Endoxifen To Treat Mammographic Breast Density
  
 
>